Clinical trials: Rosacea, Erythematotelangiectatic
Erythematotelangiectatic Rosacea
Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea
This is a randomized, double-blind, parallel-group, vehicle-controlled, dose-finding study to investigate the pharmacodynamics and the safety of three dosages of CD07805/47 topical gel (0.07%, 0.18%, and 0.50%), after a single…
- Trial name
- NCT00989014
- Testing
- CD07805/47
- Where
- 5 sites in United States
- Volunteers
- 122 people
- Sponsor
- Galderma R&D
Erythematotelangiectatic Rosacea, Papulopustular Rosacea
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
A single center prospective, randomized, controlled split face study comparing a 532nm KTP laser with a 595nm PDL for the treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea.
- Trial name
- NCT02268474
- Testing
- 532nm KTP Laser vs 595nm Pulse Dye Laser
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Cutera Inc.
Erythematotelangiectatic Rosacea, Papulopustular Rosacea
Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients
The objective of this study is to determine the efficacy and safety of PAC-14028 1% cream of Amorepacific Corporation in patients with erythema-telangiectatic or papulopustular rosacea
- Trial name
- NCT02052999
- Testing
- PAC-14028 cream 1%, Vehicle, Rozex gel 0.75%
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Amorepacific Corporation
Erythematotelangiectatic Rosacea
Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea
This study will compare treatment outcome with pulsed dye laser, when used used as an adjunctive treatment to oxymetazoline HCl 1% cream, compared to oxymetazoline HCL 1% cream alone, for patients with moderate or severe…
- Trial name
- NCT04153188
- Testing
- The Vbeam® Prima System, Oxymetazoline HCL 1% Cream
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Candela Corporation
Erythematotelangiectatic Rosacea
Feasibility Study: Ulthera System for the Treatment of Rosacea
Up to 12 subjects will be enrolled. Enrolled subjects will receive one or two Ultherapy treatments on the cheeks, depending on their assigned study group. Follow-up visits will occur 14, 30 and 90 days post-treatment.
- Trial name
- NCT01756027
- Testing
- Ulthera System providing one treatment per cheek, Ulthera System providing two treatments per cheek
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Ulthera, Inc
Erythematotelangiectatic Rosacea, Rosacea
Ultherapy® for the Treatment of Erythematotelangiectatic Rosacea
This is a prospective, multi-site (up to 5 sites), single-blinded, randomized trial. Up to 88 subjects will be enrolled and randomized to one of four treatment groups (4 Groups of 22 subjects), and will receive study treatments…
- Trial name
- NCT02144181
- Testing
- Ulthera System Treatment
- Where
- 5 sites in United States, Canada
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Ulthera, Inc
Rosacea
Effect of CD07805/47 Gel in Rosacea Flushing
Phase 2a study to assess the efficacy and safety of CD07805/47 0.5% gel in the prevention of the flush of rosacea.
- Trial name
- NCT02300129
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Galderma R&D
Rosacea
A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)
This study will assess the effect of MK-0524 relative to placebo, on signs and symptoms of rosacea and to determine the safety and tolerability profile of MK-0524 in participants with rosacea.
- Trial name
- NCT01451619
- Testing
- Laropiprant
- Volunteers
- 60 people
- Sponsor
- Merck Sharp & Dohme LLC
Papulopustular Rosacea, Erythematotelangiectatic Rosacea
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
The purpose of this study is to compare the efficacy of two Metronidazole Gels 1%, in the treatment of Rosacea.
- Trial name
- NCT02393937
- Testing
- Reference: Metronidazole Gel 1%, Test: Metronidazole Gel 1%
- Where
- 27 sites in United States
- Volunteers
- 963 people
- Sponsor
- bioRASI, LLC
Rosacea
A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea
This is a Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized Phase II trial, comparing the effect of twice daily B244 application for 8 weeks vs. vehicle application on treatment of mild to moderate rosacea.
- Trial name
- NCT03590366
- Testing
- B244, Vehicle
- Where
- 9 sites in United States
- Volunteers
- 140 people
- Sponsor
- AOBiome LLC
Rosacea Subtype 1 (Erythematotelangiectatic)
Efficacy and Tolerability of Topical Rossoseq™ Compared to Vehicle in Rosacea Subtype 1 (Erythematotelangiectatic)
Rossoseq™ is registered for the treatment of inflammatory skin conditions. Rosacea is one such inflammatory skin disorder that has not been studied yet for the use of Rossoseq™.
- Trial name
- NCT01666509
- Testing
- Rossoseq™
- Where
- 4 sites in Germany
- Volunteers
- 61 people
- Sponsor
- PBB Entrepreneur Ltd.
Rosacea, Erythematotelangiectatic, Rosacea Subtype 1 (Erythematotelangiectatic)
Dermocosmetic Treatment for Facial Redness in Rosacea With or Without Laser Therapy
The aim of this clinical study is to evaluate the effectiveness and safety of a dermocosmetic product in reducing facial redness and visible blood vessels associated with erythematotelangiectatic rosacea.
- Trial name
- NCT07521462
- Testing
- Dermocosmetic tested product, Vascular laser treatment
- Where
- France
- Volunteers
- 50 people
- Sponsor
- ISISPHARMA